Genscript Biotech Corporation
Genscript Biotech Corporation (GNNSF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gnnsf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Genscript Biotech CorporationYou GNNSF | $3.5B | N/A | — | — |
 ALK-Abelló A/S AKBLF | $6.3B | 42.58x | +22.5% | $5.39 |
 Camurus AB (publ) CAMRF | $3.5B | 49.84x | +43.4% | $12.42 |
 Carl Zeiss Meditec AG CZMWF | $2.7B | 26.20x | -24.6% | $1.61 |
 InnoCare Pharma Limited INCPF | $3.1B | 40.36x | +16.1% | $0.36 |
 Laboratorios Farmaceuticos Rovi, S.A. LABFF | $4.6B | 28.10x | -19.2% | $2.74 |
 Siegfried Holding AG SGFEF | $4.4B | 21.52x | -38.1% | $3.86 |
Industry Average 6 peers with valid PE | — | 34.77x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Genscript Biotech Corporation (GNNSF) measures how much investors pay for each dollar of the company's trailing earnings. GNNSF's current PE ratio of N/A is calculated by dividing its stock price of $1.60 by its TTM earnings per share of —.
Frequently asked questions
GNNSF pe ratio · 6 questionsGNNSF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.60 and TTM EPS of —. Data sourced from Financial Modeling Prep via GNNSF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Genscript Biotech Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09